Neurogene【NGNE】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

15.85

買値

15.00

売値

19.11

出来高

329,047

15.21 日の範囲 16.3279

14.42 52 週間の範囲 74.49

時価総額

235.447M

前日終値

15.53

始値

15.57

時刻

最終取引時間

財務取引量

US$ 5,181,554

VWAP

15.7472

平均取引量 (3 か月)

426,859

発行済株式数

14,854,725

配当利回り

PER

-6.50

1 株当たり利益 (EPS)

-2.44

歳入

純利益

-36.32M

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional ge... Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.neoleukin.com

本社

Wilmington, Delaware, USA

設立

Neurogene Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker NGNE. The last closing price for Neurogene was US$15.53. Over the last year, Neurogene shares have traded in a share price range of US$ 14.42 to US$ 74.49.

Neurogene currently has 14,854,725 shares in issue. The market capitalisation of Neurogene is US$230.69 million. Neurogene has a price to earnings ratio (PE ratio) of -6.50.

Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett syndrome Neurogene to advance NGN-401 at 1E15 vg dose Expects to provide an update on...

Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update...

Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.4	2.58899676375	15.45	16.7	14.42	251257	15.2575183	CS
4	-7.81	-33.0092983939	23.66	24	14.42	203621	17.91015892	CS
12	-53.93	-77.2857552307	69.78	74.49	14.42	426859	25.18417174	CS
26	-23.77	-59.9949520444	39.62	74.49	14.42	255424	31.24931905	CS
52	-15.65	-49.6825396825	31.5	74.49	14.42	192143	33.60852778	CS
156	1.28	8.78517501716	14.57	74.49	12.49	182061	33.22444336	CS
260	1.28	8.78517501716	14.57	74.49	12.49	182061	33.22444336	CS

NGNE - Frequently Asked Questions (FAQ)

What is the current Neurogene share price?

The current share price of Neurogene is US$ 15.85

How many Neurogene shares are in issue?

Neurogene has 14,854,725 shares in issue

What is the market cap of Neurogene?

The market capitalisation of Neurogene is USD 230.69M

What is the 1 year trading range for Neurogene share price?

Neurogene has traded in the range of US$ 14.42 to US$ 74.49 during the past year

What is the PE ratio of Neurogene?

The price to earnings ratio of Neurogene is -6.5

What is the reporting currency for Neurogene?

Neurogene reports financial results in USD

What is the latest annual profit for Neurogene?

The latest annual profit of Neurogene is USD -36.32M

What is the registered address of Neurogene?

The registered address for Neurogene is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19802

What is the Neurogene website address?

The website address for Neurogene is www.neoleukin.com

Which industry sector does Neurogene operate in?

Neurogene operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	729.72M
REBNReborn Coffee Inc	US$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	US$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	US$ 1.54 (56.50%)	13.82M
CYCNCyclerion Therapeutics Inc	US$ 3.92 (54.33%)	82.39M
ENVBEnveric Biosciences Inc	US$ 2.0899 (-46.41%)	1.58M
NIVFNewGenIvf Group Ltd	US$ 0.1489 (-42.51%)	14.91M
GLSTGlobal Star Acquisition Inc	US$ 8.83 (-39.10%)	23.93k
PRPHProPhase Labs Inc	US$ 0.2633 (-38.02%)	900.48k
SPGCSacks Parente Golf Inc	US$ 0.5601 (-37.86%)	7.42M
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	731.1M
NVDANVIDIA Corporation	US$ 120.07 (-3.67%)	388.5M
RIMEAlgorhythm Holdings Inc	US$ 0.02565 (5.12%)	341.8M
CLEUChina Liberal Education Holdings Ltd	US$ 0.1938 (30.77%)	237.15M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0355 (-11.25%)	236.44M